Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)

被引：0
|
作者：
Gregorc, V.
Novello, S.
Santoro, A.
Grossi, F.
Levra, M. Giaj
Cavina, R.
Vigano, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Univ Turin, Orbassano, Italy
[3] Ist Clin Humanitas, Rozzano, Italy
[4] Natl Inst Canc Res, Genoa, Italy
[5] Univ Turin, AUO San Luigi, Thorac Oncol Unit, Orbassano, Italy
[6] Ist Clin Humanitas, Dept Oncol, Rozzano, Italy
[7] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18043
引用
收藏
页数：1
相关论文
共 50 条
  • [11] NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer
    Gregorc, Vanesa
    Cavina, Raffaele
    Novello, Sivia
    Grossi, Francesco
    Lazzari, Chiara
    Capelletto, Enrica
    Genova, Carlo
    Salini, Giulia
    Lambiase, Antonio
    Santoro, Armando
    ONCOLOGIST, 2018, 23 (10): : 1133 - +
  • [12] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
    Gregorc, Vanesa
    De Braud, Filippo G.
    De Pas, Tommaso M.
    Scalamogna, Roberto
    Citterio, Giovanni
    Milani, Alessandra
    Boselli, Sabrina
    Catania, Chiara
    Donadoni, Giovanni
    Rossoni, Gilda
    Ghio, Domenico
    Spitaleri, Gianluca
    Ammannati, Cristina
    Colombi, Scialini
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1964 - 1972
  • [13] Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy
    Santoro, Armando
    Rimassa, Lorenza
    Sobrero, Alberto F.
    Citterio, Giovanni
    Sclafani, Francesco
    Carnaghi, Carlo
    Pessino, Anna
    Caprioni, Francesco
    Andretta, Valeria
    Tronconi, Maria Chiara
    Finocchiaro, Giovanna
    Rossoni, Gloria
    Zanoni, Angela
    Miggiano, Chiara
    Rizzardi, Gian-Paolo
    Traversari, Catia
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (15) : 2746 - 2752
  • [14] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Noberasco, C.
    Boselli, S.
    Giovannini, M.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
  • [15] Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [16] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    De Braud, F. G.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [17] NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 509 - 509
  • [18] NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study
    Rimassa, L.
    Santoro, A.
    Sobrero, A. F.
    Sclafani, F.
    Gregorc, V.
    Andretta, V.
    Tronconi, M. C.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [19] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [20] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Rimassa, L.
    Sobrero, A. F.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345